Focus Partners Wealth
AZN icon

Focus Partners Wealth’s AstraZeneca AZN Stock Holding History

Focus Partners Wealth’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6M Buy
68,950
+4,999
+8% +$964K 0.02% 619
2025
Q4 		$11.6M Buy
63,951
+12,853
+25% +$2.25M 0.01% 655
2025
Q3 		$7.89M Buy
51,098
+9,576
+23% +$1.45M 0.01% 626
2025
Q2 		$5.8M Buy
41,522
+1,702
+4% +$239K 0.01% 635
2025
Q1 		$5.85M Buy
39,820
+4,799
+14% +$694K 0.01% 587
2024
Q4 		$4.59M Buy
35,021
+3,367
+11% +$471K 0.01% 634
2024
Q3 		$4.92M Buy
31,654
+9,383
+42% +$1.51M 0.02% 565
2024
Q2 		$3.47M Buy
22,271
+2,549
+13% +$384K 0.01% 560
2024
Q1 		$2.67M Buy
19,722
+5,037
+34% +$667K 0.02% 435
2023
Q4 		$1.98M Buy
+14,685
New +$1.91M 0.03% 356

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Focus Partners Wealth's AZN Position: Q1 2026 in Review

Focus Partners Wealth increased its AstraZeneca (AZN) stake by 7.8% in Q1 2026, buying an estimated $964K and bringing the position to 68,950 shares worth $13.6M. The position accounts for 0.02% of the portfolio, ranked #619.

Focus Partners Wealth first reported a position in AZN in Q4 2023 and has held it in 10 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Focus Partners Wealth held 68,950 shares of AstraZeneca worth $13.6M as of Q1 2026.
  • Focus Partners Wealth bought 4,999 AstraZeneca shares in Q1 2026, an estimated $964K.
  • AstraZeneca made up 0.02% of Focus Partners Wealth's portfolio in Q1 2026, its #619 holding.
  • Focus Partners Wealth first reported a position in AstraZeneca in Q4 2023 and has held it in 10 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.